Enhancing Operational Performance in Healthy Rested Soldiers With Pharmacological Stimulants

NCT ID: NCT03893032

Last Updated: 2019-07-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-07-17

Study Completion Date

2019-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Considerable research has documented the optimization utility of stimulants in sleep deprived Soldiers and aviators, however, the research for enhancement purposes has demonstrated mixed results. One significant factor that may influence enhancement properties is general intelligence such that low performers exhibit stronger enhancement effects than high performers. The objective of this study is to determine whether stimulants (specifically, modafinil and Adderall) can enhance Soldier cognitive abilities and performance on military tasks. To do so, a within-subjects design will be employed using healthy, rested Soldiers and measuring performance on a set of basic cognitive assessments and operationally relevant tasks.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cognition

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Modafinil 200mg

single, 200 mg dose of modafinil

Group Type EXPERIMENTAL

Modafinil 200mg

Intervention Type DRUG

single 200 mg dose

mixed amphetamine salts

single 10 mg dose of mixed amphetamine salts

Group Type EXPERIMENTAL

mixed amphetamine salts

Intervention Type DRUG

single 10 mg dose

placebo

placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

single oral-administration placebo tablet

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Modafinil 200mg

single 200 mg dose

Intervention Type DRUG

mixed amphetamine salts

single 10 mg dose

Intervention Type DRUG

Placebo

single oral-administration placebo tablet

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Must be at least 18 years old.
* Must have normal hearing, vision or corrected to normal vision, and cognitive function as determined by self-report
* Must have obtained at minimum 6 hours of sleep prior to all testing sessions, as assessed by actigraphy data and self-report. Should the actiwatch malfunction, reliance on self-report will suffice. If the subject does not meet this requirement, he will be asked to reschedule
* Must have refrained from consumption of stimulants (including caffeine) and over the counter medications which may induce drowsiness for a minimum of 16 hours prior to each test session, and nicotine, 8 hours, prior to all testing sessions, assessed by self-report.

Exclusion Criteria

* Currently taking medications which induce drowsiness, such as over-the-counter antihistamines. Any self-medication will be assessed through self-report.
* No current medical conditions or medications affecting cognitive function or attention as determined by screening by study physician or medical practitioner
* Current or recent use (as determined by study physician or medical practitioner) of medications that may interact with the test articles. Determined by self-report and exclusion at the discretion of the study physician or medical practitioner.
* Any history of any attention deficit condition requiring medication. A history of any attention deficit condition with medication is disqualifying as the potential interactions with testing are unknown and would therefore produce a potential source of confounding or bias into the results of the study.
* Any history of psychological/psychiatric disorder.
* Any history of addiction or substance abuse as assessed through self-report.
* Any history of metabolic disorder such as dysthyriodism.
* Any history of significant cardiovascular disease or hypertension.
* Any history of hepatic or renal disorder.
* Females will be excluded given that the drugs administered could potentially negatively impact the very early stages of pregnancy.
* Any ingestion of substances that may interact with the test articles or potentially skew the results within the last 16 hours prior to testing including over-the-counter medications, supplements, etc. (see attached list to be reviewed with subject).
Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

United States Army Aeromedical Research Laboratory

FED

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Amanda Kelley

Research Psychologist

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

US Army Aeromedical Research Laboratory

Fort Rucker, Alabama, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Amanda M Kelley, PhD

Role: CONTACT

Phone: 334-498-2456

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Amanda M Kelley, PhD

Role: primary

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Informed Consent Form

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

USAARL 2018-007; IRB M-10746

Identifier Type: -

Identifier Source: org_study_id